Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Insmed (NASDAQ:INSM) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $90.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on INSM. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Truist Financial increased their price target on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. UBS Group dropped their price objective on shares of Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a report on Friday. Finally, Morgan Stanley upped their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.93.

Insmed Stock Performance

NASDAQ INSM opened at $67.75 on Monday. Insmed has a 1 year low of $21.92 and a 1 year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market cap of $12.32 billion, a price-to-earnings ratio of -12.12 and a beta of 0.84. The company has a fifty day moving average price of $72.17 and a 200-day moving average price of $73.26.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) EPS. As a group, equities research analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the sale, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. This trade represents a 13.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. The trade was a 5.31% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 88,232 shares of company stock worth $6,868,473. 3.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently made changes to their positions in INSM. JCIC Asset Management Inc. boosted its position in Insmed by 40.7% during the fourth quarter. JCIC Asset Management Inc. now owns 2,560 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 740 shares in the last quarter. Capital CS Group LLC bought a new stake in Insmed during the fourth quarter valued at about $586,000. Park Avenue Securities LLC boosted its position in Insmed by 42.1% during the fourth quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company’s stock valued at $549,000 after purchasing an additional 2,358 shares in the last quarter. Atomi Financial Group Inc. boosted its position in Insmed by 6.6% during the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company’s stock valued at $1,710,000 after purchasing an additional 1,526 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 183 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.